Impact of concomitant fibrates on immunotherapy outcomes for advanced <scp>non‐small</scp> cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of concomitant fibrates on immunotherapy outcomes for advanced non‐small cell lung cancer

Published:2022-05-24 Issue:1 Volume:12 Page:358-367
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Stokes William A.¹²^ORCID,Behera Madhusmita²,Jiang Renjian²,Gutman David A.²³,Huang Zhonglu²,Burns Abigail³,Sebastian Nikhil T.¹²^ORCID,Sukhatme Vidula⁴⁵,Lowe Michael C.⁴⁶,Ramalingam Suresh S.²⁷,Sukhatme Vikas P.⁴,Moghanaki Drew⁸

Affiliation:

1. Department of Radiation Oncology Emory University Atlanta Georgia USA

2. Winship Cancer Institute Emory University Atlanta Georgia USA

3. Atlanta Veterans Affairs Health Care System Decatur Georgia USA

4. Morningside Center for Innovative and Affordable Medicine Emory University Atlanta Georgia USA

5. GlobalCures, Inc Newton Massachusetts USA

6. Division of Surgical Oncology Emory University Atlanta Georgia USA

7. Department of Hematology and Medical Oncology Emory University Atlanta Georgia USA

8. Department of Radiation Oncology University of California Los Angeles Los Angeles California USA

Funder

U.S. Department of Veterans Affairs

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4847

Reference21 articles.

1. The Effect of Advances in Lung-Cancer Treatment on Population Mortality

2. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

3. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

4. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

5. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer;Cancer Research Communications;2024-08-01

2. Readily available drugs and other interventions to potentially improve the efficacy of immune checkpoint blockade in cancer;Frontiers in Immunology;2024-01-17

3. Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis;Current Oncology;2023-09-01

4. Lipotoxicity as a Barrier for T Cell-Based Therapies;Biomolecules;2022-08-25

5. Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer;Cells;2022-08-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3